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Abstract
Background: Mutations in the fibrillin -1 gene (FBN1) cause Marfan syndrome (MFS), an autosomal
dominant multi-system connective tissue disorder. The 200 different mutations reported in the 235
kb, 65 exon-containing gene include only one family with a genomic multi-exon deletion.
Methods: We used long-range RT-PCR for mutation detection and long-range genomic PCR and
DNA sequencing for identification of deletion breakpoints, allele-specific transcript analyses to
determine stability of the mutant RNA, and pulse-chase studies to quantitate fibrillin synthesis and
extracellular matrix deposition in cultured fibroblasts. Southern blots of genomic DNA were
probed with three overlapping fragments covering the FBN1 coding exons
Results: Two novel multi-exon FBN1 deletions were discovered. Identical nucleotide pentamers
were found at or near the intronic breakpoints. In a Case with classic MFS, an in-frame deletion of
exons 42 and 43 removed the C-terminal 24 amino acids of the 5th LTBP (8-cysteine) domain and
the adjacent 25th calcium-binding EGF-like (6-cysteine) domain. The mutant mRNA was stable, but
fibrillin synthesis and matrix deposition were significantly reduced. A Case with severe childhood-
onset MFS has a de novo deletion of exons 44–46 that removed three EGF-like domains. Fibrillin
protein synthesis was normal, but matrix deposition was strikingly reduced. No genomic
rearrangements were detected by Southern analysis of 18 unrelated MFS samples negative for FBN1
mutation screening.
Conclusions:  Two novel deletion cases expand knowledge of mutational mechanisms and
genotype/phenotype correlations of fibrillinopathies. Deletions or mutations affecting an LTBP
domain may result in unstable mutant protein cleavage products that interfere with microfibril
assembly.
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Background
The Marfan syndrome (MFS) is an autosomal dominant
connective tissue disorder with an estimated incidence of
1 in 5,000 live births [1]. Besides the classic manifesta-
tions in the cardiovascular, ocular and musculoskeletal
systems, frequent features include spontaneous pneu-
mothorax, inguinal herniae, striae atrophicae in the skin
and lumbosacral dural ectasia. There is pronounced in-
ter- and intrafamilial variability. Age of onset and pro-
gression of the various manifestations cover a wide range
[1,2].
The MFS phenotype is the result of mutations in FBN1, a
large gene composed of 65 exons encoding the 350 kD fi-
brillin-1 protein that is the major constituent of microfi-
brils in the extracellular matrix (reviewed in [3]). To
date, 201 unique FBN1 mutations have been identified,
including 70 (34.8%) cysteine substitutions, 63 (31.3%)
other missense mutations, 41 (20.4%) premature termi-
nation mutations, 23 (11.4%) exon skipping mutations,
and 4 other mutations, as listed in the Human Gene Mu-
tation Database (HGMD,  [http://archive.uwcm.ac.uk/
uwcm/mg/search/127115.html] ) [4] and reported more
recently [5]. Although the FBN1 gene, including three al-
ternatively spliced 5' untranslated exons [6] extends over
235 kb of genomic DNA in chromosome band 15q21.1
[http://genome.cse.ucsc.edu] , no major deletions have
been identified except for one report of an exon 60–62
genomic deletion [7]. Some correlations between FBN1
mutation genotypes and phenotypes are emerging. For
example, exon-skipping mutations in the central region
of the gene, exons 24–32, cause severe phenotypes or ne-
onatal presentations [8]. But there are exceptions, only
four of the many other mutations in this region cause se-
vere phenotypes, while one mutation predicted to lead to
skipping of exon 24 was found in a patient with classic
MFS [5]. In contrast, most cysteine substitutions cause
classic MFS with a high frequency of lens dislocation, al-
though some patients in our study did not meet the Gh-
ent criteria for diagnosis of MFS [9]. Amino-acid
substitutions not disrupting disulfide bonds may be as-
sociated with fibrillinopathies other than MFS, although
mutations in the calcium-binding consensus sequence
have been reported in individuals with classic MFS
[5,10–12]. It is clear from the studies reported so far, that
genotype-phenotype correlations are not straight-for-
ward for FBN1 mutations.
We report here two multi-exon deletion mutations of
FBN1 . We located the deletion breakpoints in introns
and characterized the mutant RNA and protein pheno-
types. Partial deletion of an 8-cysteine (LTBP-like) do-
main and loss of the downstream 6-cysteine calcium-
binding (cb) epidermal growth factor (EGF)-like domain
caused protein instability and classic MFS. De novo dele-
tion of three cbEGF-like domains encoded by exons 44–
46 resulted in a severe form of MFS diagnosed in infancy.
Both mutations lead to the synthesis of mutant FBN1
proteins that interfere with microfibril assembly, result-
ing in significantly reduced extracellular matrix microfi-
brils.
Patients and Methods
Clinical histories
Case 1
(FB774): Patient 1, a female, was born to a 36 yr old fa-
ther and was noted to have long fingers at birth. A diag-
nosis of MFS was made at age 15 yr, based on bilateral
lens dislocation (upward) and Marfanoid skeletal fea-
tures. Diffuse red and pink cutaneous striae started to
appear at age 15, when obesity developed, and pro-
gressed throughout life. As an adult, Patient 1 had a
height of 186 cm with long arms and legs, a narrow high-
ly arched palate and dental crowding, chest asymmetry
and pectus deformity (upper sternum protrudes), hyper-
extensible large and small joints, arthritis, arachnodac-
tyly, frequent thumb dislocations, pes planus, and thin,
fragile skin. Besides ectopia lentis, ocular features in-
cluded high-grade myopia and glaucoma requiring sur-
gery at age 18 yr. A cardiac arrhythmia was treated with
beta-blockers. The aortic root diameter was 4.5 cm by
echocardiogram at 46 yr of age. A skin biopsy for fibrob-
last culture was obtained at age 40 yr. There was no fam-
ily history of MFS, both parents were deceased.
Case 2
(FB 890): Born to a 27 yr old mother and 34 yr old father,
Patient 2 presented as a neonate with striking arachn-
odactyly and pectus excavatum. At 4 months, her skeletal
measurements were all above the 97th %ile (length 66
cm, arm span 67 cm, middle finger length 5 cm, foot
length 10 cm) and the upper-to-lower segment ratio of
1.27 was significantly below normal for age. She had mild
contractures of elbows and knees, a long face with deep-
set eyes, bilateral iridodonesis and high-grade myopia.
Bilateral lens dislocation was confirmed at age 3 yr. Dur-
ing early childhood, she developed severe progressive
thoracolumbar scoliosis (>80 degrees) requiring spinal
fusion procedures. Episodes of supraventricular tachy-
cardia and cardiac arrhythmia were treated with cardio-
version and beta-blockers. Starting in infancy, her aortic
root dilated rapidly to a diameter of 4.5 cm at age 6 yr.
She developed mitral regurgitation and mitral and tri-
cuspid valve prolapse. Her joints became increasingly
hypermobile. Before valve-replacement surgery, her se-
vere pectus excavatum was repaired. Throughout child-
hood, she had underdeveloped musculature and lack of
subcutaneous fat. To improve her nutritional status, she
received nasogastric tube feedings at night. Photos of Pa-BMC Medical Genetics 2001, 2:11 http://www.biomedcentral.com/1471-2350/2/11
tient 2 were recently published (Figure 13.2 a-d in [13]).
There was no family history of MFS.
PCR and direct sequencing
Genomic DNA and total RNA were extracted from fi-
broblast cultures established from skin biopsies as de-
scribed [14]. Long-range RT-PCR amplification of FBN1
cDNA fragments and restriction enzyme digestions were
performed as previously reported [8]. Fragments mi-
grating abnormally in agarose gel electrophoresis were
excised, purified with the QIAquick Gel Extraction Kit
(QIAGEN) and directly sequenced with fluorescent ter-
minators on an ABI Prism 377 DNA sequencer (Perkin-
Elmer). To define the deletion endpoints, we amplified
genomic DNA with the ExpandTM PCR System (Boe-
hringer Mannheim). The thermal profile for long-range
PCR was as follows: denaturation for 2 min at 94°C, then
35 cycles of denaturation (10 s at 94°C), annealing (30 s
at 60°C), and extension (8 min at 68°C), followed by a fi-
nal extension step of 7 min at 68°C.
Primers used for genomic amplifications and their loca-
tion in exons:
774F, 5'-AAGCCCTCTGAACAGTGTCCCATCCCAAGT-3'
(exon 41);
774R, 5'-TTGCACTGTCCTGTGGAGGTGAAGCGGTAG-
3' (exon 44).
890F, 5'-AGATCCCAGGGGTCTGTGAAAATGGAGTGT-
3' (exon 43);
890R, 5'-TTGCACTGGCACTGGAAAGACCCCACTGTA-
3' (exon 47)
We purified the genomic amplicons with exonuclease
and shrimp alkaline phosphatase (United States Bio-
chemical) and sequenced them directly with primers
E41S, E43S, E44AS and E47AS [15].
To sequence the junction fragments from both strands,
we performed PCR and sequencing with primers 774F
and reverse primer E43+355 (5'-CAA AGT CTC TGT CTG
GAA GAG AAA TGA TTT TGA-3') for FB774, and with
forward primer E44 -343 (5'-CCT TAG CTT CCC AAA
GTG CTA GGA TTA-3') and 890R for FB890.
Quantitation of allele-specific FBN1 transcripts
Patient 1 was heterozygous for the RsaI polymorphism in
the 3'UTR. RT-PCR and RsaI digestion were carried out
as described [16]. The products of the two alleles were
distinguished by SSCA and silver staining, according to
the protocol provided by the manufacturer (Bio Rad,
Hercules, CA), and were subsequently quantified by
scanning densitometry.
Quantitative pulse-chase analysis of fibrillin-1 protein
Primary fibroblast cultures from patients and control in-
dividuals were grown to confluency and then metaboli-
cally labeled with 35S-cysteine as described [17,18]. The
soluble cell lysis fraction, containing newly synthesized
labeled fibrillin-1 molecules, and the insoluble fraction,
representing the labeled fibrillin in the extracellular ma-
trix, were fractionated by SDS polyacrylamide gel elec-
trophoresis and autoradiographed. Labeled fibrillin-1
was identified and quantified as described [17,18]. More
recently, the results were replicated by use of a phos-
phorimager. The levels of fibrillin-1 production and dep-
osition in the extracellular matrix were expressed as the
percentage of values obtained for simultaneously studied
normal control fibroblast cultures.
Results and Discussion
We developed a long RT-PCR approach to screen for
exon-skipping and large deletion mutations in the FBN1
gene. PCR with three sets of primer pairs amplifies over-
lapping fragments: exons 1 – 31 (3972 bp), exons 29 – 52
(3011 bp) and exons 47 – 65 (2971 bp) from skin fibrob-
last-derived total RNA. The amplicons are digested with
restriction enzymes that generate individually recogniz-
able fragments with known sequence content. A total of
60 patients were screened with this method, 55 of which
met diagnostic criteria for MFS and 5 had partial mani-
festations. All of these skin fibroblast samples had previ-
ously been screened with a cDNA amplification/SSCA
protocol [14] and a genomic DNA/exon amplification
method [15] with negative results. As reported previous-
ly, the long RT-PCR method identified six samples with
transcripts skipping exons 18, 31, 46, 49, 56 or 58 that
were caused by nucleotide substitutions at splice sites
[8]. In another patient, skipping of exon 51 was discov-
ered to be due to a silent mutation within the exon, pos-
sibly affecting a splicing enhancer binding site [19]. Here
we report abnormal fragments seen after TaqI digestion
of the exon 29–52 amplicons (Fig. 1a). Sequence analysis
of the altered cDNA fragments revealed a deletion of ex-
ons 42 and 43 in patient 1 and a deletion of exons 44–46
in patient 2 (Fig. 1b).
In both cases, we found no evidence for sequence altera-
tions, when we amplified the deleted and flanking exons
and their splice sites individually from genomic DNA
(data not shown). Therefore, we suspected that these
normal amplification products were derived from the
normal FBN1 alleles, and that the mutant alleles were
not amplified by this approach because they carry gross
genomic deletions. To test this hypothesis, primer pairs
were designed from the flanking exon sequences for am-BMC Medical Genetics 2001, 2:11 http://www.biomedcentral.com/1471-2350/2/11
plification of genomic DNA. Long-range PCR analysis re-
vealed genomic deletions, about 5 kb in size, in both
patients (Fig. 2). For Case 1 (P1), a 4 kb amplicon was ob-
tained instead of the 9 kb amplicon in the normal control
sample. For Case 2 (P2), a 4.2 kb product was amplified
instead of the 9.2 kb product in the normal control. In
both cases, the PCR conditions used favored the amplifi-
cation of the shorter (mutant) fragment, although the
normal allele was also present in the genomic PCR tem-
plate (Fig. 2). Direct sequencing of the deletion junction
amplicons revealed the location of the intronic break-
points. Both deletion events generated clean junctions
with no missing or inserted nucleotides. In Case 1, the
breakpoints are about 300 nt downstream from exons 41
and 43, while in Case 2, they are located about 300 nt up-
stream of exons 44 and 47. In Case 1, two sets of identical
pentamers (cagta and ggaaa) were identified near the
breakpoints in introns 41 and 43. In Case 2, the exchange
occurred within an identical pentamer (atttt) (Fig. 2).
None of these sequences are known to predispose to ge-
nomic rearrangements, although short stretches of iden-
tical sequence are often found at the sites of germline
translocation and deletion breakpoints [20–22]. Ge-
nomic analysis of the parents and siblings of Case 2 indi-
Figure 1
(a) Comparison of the TaqI restriction fragment patterns of long RT-PCR products containing FBN1 exons 29–52. Sample C is
amplified from a normal control, PI represents patient 1 (FB774) and P2 patient 2 (and FB890). Lane 1 is a 100 bp ladder.
Arrows point to the abnormal fragments in the patient lanes. (b) Direct sequencing analysis of the DNA isolated from the
altered restriction fragments reveals deletion of exons 42–43 in patient 1 (top) and of exons 44–46 in patient 2 (bottom).BMC Medical Genetics 2001, 2:11 http://www.biomedcentral.com/1471-2350/2/11
cated that the mutation was sporadic. Although the
parents of Case 1 were not available for study, the nega-
tive family history suggests that this deletion is also de
novo. Slightly advanced paternal age (36 yr and 34 yr, re-
spectively) may be a factor in both cases.
The effects of the two deletions were studied at the pro-
tein level by 35S-cysteine pulse-chase analysis. Both mu-
tant mRNAs encode internally deleted proteins without
a frameshift. In Case 2 with del exons 44–46, fibrillin
synthesis was normal (109% of control), indicating that
Figure 2
Left: Long PCR analysis of genomic DNA indicates about 5 kb deletions in both patients PI and P2. Lane 1 (Std) is a 1 kb ladder.
Arrows point to the abnormal fragments generated by the genomic deletions. Sample N is amplified from a normal control.
Right: Schematic representation of the deletion regions of the genomic DNA (shaded). Bottom: Sequence analysis of junction
fragments amplified by PCR reveal identical pentamers (bold). In Case 1, the nucleotide (t) at position +325 in intron 41 is
joined to the nucleotide (c) in position +314 in intron 43. In Case 2, the breakage and rejoining occurred within the pentamer
(atttt) at positions -282 to -278 of intron 43 and positions -325 to -321 of intron 46.BMC Medical Genetics 2001, 2:11 http://www.biomedcentral.com/1471-2350/2/11
Figure 3
A. As a measure for fibrillin synthesis, the two left lanes show labeled fibrillin (arrow head) detected in the cytosol of fibrob-
lasts from a normal control (CR) and from Case 1 (774) after a 30 min pulse with 35S-cysteine. The amount in lane 774 is 55%
of that in lane CR. In the right four lanes, the incorporation of pulse-labeled fibrillin (arrow head) into the extracellular matrix,
after 8 hour and 20 hour chase periods, is severely reduced in Case 1 (774/8 and 774/20) compared to the normal control
fibroblasts (C8 and C20). B. Allele-specific RNA analysis. All individuals are heterozygous for the C6236T RsaI polymorphism
in the FBN1 3'UTR. RT-PCR products from fibroblast RNA samples were digested with RsaI and electrophoresed on an SSCA
gel under denaturing conditions. The band labeled T represent the uncut T allele, the two bands labeled C represent the cut C
allele, and the band marked by asterisk is constant. Samples 1 and 5 are normal controls, sample 2 has an exon 51 skipping
mutation [19], and the sample in lane 4 is from Case 1 (774) with deletion of exons 42 and 43. Both these samples, as well as
the one in lane 7 show the normal pattern of fragments indicating equal transcripts of both alleles. In contrast, sample 3 reveals
predominant transcripts with the C allele, while in samples 6 and 8 only the T allele is detectable. Lane 9 shows slight skewing
towards the C allele. Samples 3 and 8 have FBN1 mutations leading to premature stop codons. For samples 6,7 and 9, no FBN1
mutations have been identified as yet.BMC Medical Genetics 2001, 2:11 http://www.biomedcentral.com/1471-2350/2/11
the mutant fibrillin molecules are stable. The mutant
protein band, expected to be 122 amino acids shorter,
was not resolved on our gel system. The deposition of
newly synthesized fibrillin into the matrix was greatly re-
duced (13 % of normal), however, suggesting that the in-
ternally deleted mutant fibrillin-1 molecules are secreted
and exert a dominant-negative effect on extracellular mi-
crofibril assembly.
In Patient 1, the in-frame deletion of exons 42–43 re-
moved the C-terminal 24 amino acids of the 5th LTBP (8-
cysteine) domain and the adjacent 25th calcium-binding
EGF-like domain. Fibrillin synthesis levels were 55% of
control and, in addition, matrix deposition was dispro-
portionately reduced to 16% of control (Fig. 3A). An ear-
lier independent study of this patient's fibroblasts had
revealed similar results: 34% for synthesis and 11% for
deposition (T. Aoyama, unpublished data). To determine
whether the low value for synthesis was due to reduced
mutant transcript levels, we made use of the RsaI restric-
tion site polymorphism in the FBN1 3'UTR for which the
patient is heterozygous. The SSCA patterns of RsaI di-
gested RT-PCR products were indistinguishable from
controls, indicating that transcript levels were equal for
both alleles (Fig. 3B). This leads us to conclude that the
mutant mRNA is stable but that the mutant protein, con-
taining a partially deleted LTBP-domain, if synthesized,
is unstable and may be processed to smaller fragments
by proteolytic cleavage. The methods we used did not al-
low us to detect such hypothetical proteolytic fragments.
Of more than 200 FBN1 mutations reported, only one is
a multi-exon deletion [7]. It involves deletion of exons
60–62 encoding three contiguous cbEGF-like domains
[23]. This deletion co-segregated with affected status in
a 3-generation family. Skeletal involvement was charac-
terized by a moderate Marfanoid habitus with mild scol-
iosis and hypermobility of large and small joints. Ectopia
lentis was absent. Retinal detachment was reported in
one individual. Cardiovascular features included aortic
dilatation in mid-life, one case of dissection at age 56 yr,
and a high frequency of mitral valve prolapse associated
with arrhythmia. Immunoprecipitation studies with fi-
brillin-specific antibodies revealed the presence of a 15
kD-smaller mutant polypeptide in the medium of meta-
bolically labeled mutant fibroblasts [7]. The shortened
molecule was incorporated into the extracellular matrix
and apparently caused major disruptions of microfibrils
[23].
Patient 2 described here also has a deletion of three con-
tiguous cbEGF-like domains, those encoded by exons
44–46. This deletion resulted in a more severe pheno-
type with onset in infancy and a rapidly progressing clin-
ical course. Thus, it appears that deletion of three
contiguous EGF-like domains can have different effects
depending on their location within the fibrillin-1 mole-
cule. Deletion of the EGF-like domains encoded by exons
60–62 in the C-terminal domain of fibrillin-1 results in a
much less severe phenotype than deletion of three EGF-
like domains in the second longest stretch of EGF-like
domains (between exons 43–49). It has been reported
that 40% of mutations identified in the region between
exons 59–65, but only 7% of mutations in other regions,
were associated with mild Marfan-like phenotypes [12].
Our results are in line with the notion of this general gen-
otype-phenotype correlation.
Deletion of one EGF-like domain due to exon skipping,
especially in the region between exon 24 and 32, usually
causes severe neonatal-onset MFS [8,24,25]. Similar de-
letions in other regions of fibrillin-1 may also result in
early onset of cardiovascular symptoms [8]. Patient 1,
described here, had a genomic deletion of exons 42 and
43 that results in an in-frame deletion of part of the 5th
LTBP-like domain and the adjacent downstream cbEGF-
like domain. Diagnosed as a teenager, patient 1 had the
skeletal and skin findings of MFS, bilateral dislocated
lenses and, at the age of 46 yr, a mildly dilated aortic
root. In contrast to the cases with deleted EGF-like do-
mains, her mutant protein was unstable. We obtained a
similar result in a case of exon 51 skipping due to a silent
C>T transition at a CpG dinucleotide [19]. In-frame dele-
tion of exon 51 removes 22 amino acids of the 6th LTBP-
like domain. In this patient's fibroblasts, fibrillin synthe-
sis was 41% of control and deposition was reduced to 5%,
while the mutant mRNA level was normal as shown here
in Fig. 3. In addition, we found that certain cysteine sub-
stitutions in EGF-like domains and located immediately
N-terminal of LTBP-like domains, cause protein insta-
bility and greatly reduced matrix deposition [9]. Taken
together, our data support a model in which misfolding
or partial deletion of LTBP-like domains results in prote-
olytic cleavage of the mutant fibrillin molecules. We hy-
pothesize that truncated intermediates interfere with
microfibril assembly and, thus, produce the low levels of
matrix deposition observed. This hypothesis is not only
based on analysis of Case 1 reported here but on a similar
analysis of five previously reported cases, one with exon
51 skipping [19] and four with cysteine substitutions im-
mediately N-terminal of the LTBP like domains [9]. It is
also possible, however, that proteolytic fragments of the
mutant protein associate with the normal length fibrillin
molecules and inhibit their secretion. Future focused
mechanistic studies are needed to test our hypothesis.
The FBN1 mutation detection rate for individuals with
clinically diagnosed MFS is currently about 75% when
the gene is completely screened with a DNA-based PCR
amplification protocol of individual exons [15,26]. Ge-BMC Medical Genetics 2001, 2:11 http://www.biomedcentral.com/1471-2350/2/11
nomic deletions such as the ones reported here are not a
frequent cause of human disease and would be missed by
this approach. To search for additional large genomic re-
arrangements, we carried out Southern analyses of Bam-
HI,  SacI and BglII digested genomic DNA from 18
fibroblasts strains that were negative for FBN1 mutation
screening by other methods, but had shown abnormal fi-
brillin biosynthetic profiles by pulse-chase analysis. The
blots were hybridized successively with the three over-
lapping long-range RT-PCR fragments covering the
FBN1 coding region, that were generated from a normal
cDNA template as described above. While we identified
several restriction fragment length polymorphisms, no
evidence for major deletions or rearrangements was
found (data not shown). Thus, we have only detected two
genomic deletions out of 105 unique disease-causing
FBN1 mutations identified in our laboratory. The Hu-
man Gene Mutation Database (as of 08/14/01) contains
23,345 unique mutations in 1069 genes. Of those, 1166
(5%) are gross deletions  [http://archive.uwcm.ac.uk/
uwcm/mg/hgmd0.html]  [27] suggesting that more
FBN1 genomic deletions await recognition. Multi-exon
deletions are easily detected with the long RT-PCR meth-
od we used here, that requires RNA from fibroblast cul-
tures, while Southern blot analyses of genomic DNA are
much more laborious and more difficult to interpret.
Whereas most published genotype-phenotype correla-
tion studies compare the nucleotide changes at the DNA
level with the list of phenotypic features, we feel strongly
that studies of the mutant alleles at the RNA and protein
level are necessary to take some of the guesswork out of
these correlations.
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